Marc Foidart
Co-Founder @ EyeD Pharma
Seraing, Belgium
Marc Foidart is a Series B investor at EyeD Pharma in Seraing focused on Biotechnology and Medical. Marc Foidart is based out of Seraing, Liege, and is the Co-Founder of EyeD Pharma. Marc previously worked at UniD Manufacturing as a CEO and Executive Chairman.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Marc Foidart invests in
Stages Marc Foidart invests in
Countries Marc Foidart invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 2 (50%)
- Health Care 2 (50%)
- Therapeutics 2 (50%)
- Pharmaceutical 2 (50%)
Stage
- Series B 2 (50%)
- Series A 1 (25%)
- Funding Round 1 (25%)
Country
- Belgium 2 (50%)
- France 1 (25%)
- The Netherlands 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Imcyse
|
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. | $31.4M / Series B / Jun 18, 2019 | |
Magnisense
|
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires | $5.5M / Oct 26, 2018 | |
Ncardia
|
Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.The company uses hiPSC stem cell technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers to bringpredictive human disease biology and accelerate drug discovery. | $11.5M / Series B / Nov 17, 2017 | |
Cell Matters
|
Cell Matters specializes in cell therapy productivity, turning cryopreservation into a competitive advantage. It offers an integrated set of GMP services, in line with regulatory, quality, and GMP requirements of the cell therapy industry. | Series A |
Co-Investors
About EyeD Pharma
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.
EyeD Pharma Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Marc Foidart
Co-Founder
|
|||
|
Jean-Marie Rakic
Board & Founding Member
|
|||
Melanie Mestdagt
CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Marc Foidart invest in?
Marc Foidart invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Marc Foidart?
Public channels for Marc Foidart include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Marc Foidart last invest?
The most recent investment recorded for Marc Foidart closed in Jun 2019. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
